Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.38M$9.38Mderivedno prior Q4 2023 on file Net Income-$33.03M-$33.03MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$36,128,000N/M Operating Cash Flowderived-$35,481,000N/M Free Cash Flowderived-$35,481,000N/M Margins · derivedOperating margin-385.2%
Net margin-352.2%
ended Dec 31, 2024 · filed Mar 13, 2025 · 72 d after period end